Eagle Genomics, a Cambridge, England, UK-based TechBio platform business applying network science to biology, raised a USD 20m first close of its scale-up funding round.
The round is being led by abrdn plc, with continued participation from existing investors Environmental Technologies Fund, and a consortium of investors headed by Granpool Innovative Investments. The current funding round will remain open for a further period to enable additional participation up to a further USD 10m.
The investment will support further development of the e[datascientist]™ platform and will continue to drive expansion into global markets and the deepening of client impact.
Led by Anthony Finbow, CEO, Eagle Genomics provides the AI-augmented knowledge discovery platform, e[datascientist]™, which empowers scientists to exploit multi-dimensional data to conduct science-led innovation for next-generation products. It supports the entire innovation workflow – from hypothesis through insight to product claims – helping bring novel, safer and sustainable products to market, faster, across the Food and Nutrition, Beauty and Personal Care, AgBio and BioPharma industries.
The system is powered by network science and multilayer hypergraphs, applying machine learning and AI to provide a data-driven insight journey into solving complex problems at scale. It integrates active learning at every step of the microbiome innovation journey, from ‘descriptive’ to ‘predictive,’ while identifying mechanisms of action.
Particular innovation journeys that enable differentiated products and product claims include:
Food and Nutrition: Personalised and functional nutrition; e.g., energy balance, feed efficiency, growth rate, botanicals, food as medicine, precision fermentation, alternative proteins and ingredient design and differentiation.
Beauty and Personal Care: Personalised/stratified cosmetics; e.g., skin, oral, scalp, pre/pro/postbiotics, ingredient manufacturing, cosmeceuticals, and genital health/personal hygiene products.
AgBio: Biofertilizers, microbiome engineering, bioavailability, crops (yield increase, protection, fertility, productivity, climate adaptation/change mitigation), soil treatment, and smart agriculture.
BioPharma: Microbiome therapeutics, anti-microbial resistance, personalised/stratified medicine, therapeutics for gastrointestinal and infectious diseases, immuno-oncology/autoimmune disease and metabolic health.
The company has sites in London’s Knowledge Quarter, Hyderabad India, New York’s Genome Center as well as Paris’ Station F, Potsdam Science Park, Germany and Kyiv, Ukraine.
FinSMEs
01/11/2022